Most Read

The regulatory agency has ascertained that the application is sufficiently finished to allow a substantive review. Valneva, a specialty vaccine company, stated that the review is classified as

The once-daily oral medication FILSPARI has been designed to target two critical pathways selectively in the disease progression of IgAN (endothelin-1 and angiotensin II). It is said to

In September last year, Stimufend received approval from the US Food and Drug Administration (FDA) to be used in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs that

Under the terms of the agreement, Coya obtained the rights for the development and commercialisation of its product COYA 301 as a single agent to treat several autoimmune

RNDP-001 is an iPSC-derived dopamine neuron progenitor intended to treat inherited as well as idiopathic forms of Parkinson’s disease. The company will submit an investigational new drug (IND)

The partnership will combine the research capabilities of Dr Emyr Lloyd-Evans & Dr Helen Waller-Evans in lysosomal biology, MDI’s drug discovery capabilities and the fragment-based drug discovery platform

Jemperli has been designed to attach to the PD-1 receptor and blocks its interaction with the PD-L1 and PD-L2 ligands. The antibody received accelerated approval in April 2021

The two firms expect the agency to recommend marketing authorization approval for the monoclonal antibody AVT04, as soon as in the second half of this year. Stelara is

Adtralza has received approval to treat AD in people aged 12 to 17 years whose disease is not adequately controlled with topical prescription therapies or when those therapies